Orthopaedic oncologist Dr. Michelle Gert shares how she scaled the field’s first large RCTs—pivoting from bench science to global, multicentre trials—while staying “scrappy” on limited resources. She unpacks the landmark PARITY study (1 vs 5 days of postoperative antibiotics), lessons on building high-performing international networks (including low-resource sites), and pragmatic tips for data quality, ethics/contract navigation, and surgeon-led enrollment. Gert also looks ahead: the promise of real-time global collaboration, the peril of AI-generated “fake” science, and why journals must double down on rigor and transparency to keep research practice-changing.